Cholinesterase inhibitor and NMDA receptor antagonist combination

This page covers all Cholinesterase inhibitor and NMDA receptor antagonist combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Acetylcholinesterase and NMDA receptor.

Targets

Acetylcholinesterase and NMDA receptor

Marketed (1)

• Rivastigmine, memantine · Novartis · Neurology
  This combination drug enhances acetylcholine levels in the brain while blocking NMDA receptor overactivity to slow cognitive decline in Alzheimer's disease.

Patent intelligence

• cholinesterase inhibitor and nmda receptor antagonist combination patent landscape — aggregated cliff calendar, attackable patents, originator estates